Monday, November 20, 2017

© Reuters.  ZIOPHARM commences early-stage study of gene therapy Ad-RTS-hIL-12 in pediatric brain tumors© Reuters. ZIOPHARM commences early-stage study of gene therapy Ad-RTS-hIL-12 in pediatric brain tumors

  • The first patient has been dosed in a Phase 1 clinical trial evaluating ZIOPHARM Oncology ‘s (ZIOP +0.5%) gene therapy Ad-RTS-hIL-12 with veledimex in pediatric patients with brain tumors.
  • The open-label study has two arms: one comprised of patients with recurrent/progressive brain tumors in the cortex and the other with patients with diffuse intrinsic pontine glioma. According to ClinicalTrials.gov, the estimated completion date is December 2019.
  • Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of interleukin-12 (IL-12), an essential protein for stimulating a T cell immune response to cancer. Veledimex is an oral activator ligand or “gene switch” which is used to control the expression of IL-12, a pro-inflammatory cytokine that produces serious side effects if over-expressed.
  • Now read: Being Careful With Sarepta Here

Original article

sponsoredArticle = ‘div-gpt-ad-1466339494851-0’;

Banner Content

FOLLOW US

GOOGLE PLUS

PINTEREST

FLICKR

INSTAGRAM

Archivies